STOCK TITAN

Sarissa Condemns Poor Corporate Governance at Alkermes

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Negative)
Tags

Alkermes governance among worst that Sarissa has seen

Alkermes’s board appears to be manipulated by CEO who has destroyed shareholder value for years

Independent directors appear to give nominating and governance only lip service

GREENWICH, Conn.--(BUSINESS WIRE)-- Sarissa Capital Management LP (“Sarissa”) today made the following statement regarding Alkermes plc (NASDAQ: ALKS):

Sarissa is disappointed that our discussions with Richard Pops, CEO of Alkermes, regarding the nominations of directors was abruptly ended by the company’s sudden announcement of its slate of nominees for the upcoming annual meeting. We were shocked that this occurred because no independent director has reached out or talked to us. This behavior represents some of the worst corporate governance that we have seen in our many years of advocacy for sound corporate governance and for companies to be run in the interests of shareholders.

Pops has presided over tremendous shareholder value destruction since becoming CEO of Alkermes over thirty years ago. Notably, in the last five years (2017-2021), despite growing revenues and having revenues over $1 billion, Alkermes has consistently operated at a net loss. During the same period, Alkermes has underperformed the IBB by approximately 130%1.

Despite the company’s history of poor performance under Pops, the board in its oversight role appears not to take its independence and fiduciary duties seriously. Despite Sarissa being one of Alkermes’ largest shareholders and our history of shareholder value creation, the governance committee made no effort at all to speak with us or our candidates.

The independent directors' recommendation of a board slate for election should take into account the views of shareholders. Accordingly, governance committees generally feel they have a duty to understand why a shareholder wants to nominate directors and at least speak to those candidates.

At Sarissa, we have nominated directors to many companies, and we cannot think of any instance in which independent directors did not speak directly with us. We believe it is possible the entire process at Alkermes was controlled by Pops who manipulated the rest of the board members. Independent directors should run the nomination process and determine the board slate.

As Alkermes and shareholders are aware, we have a proven track record of creating shareholder value. We will not stand by to witness this offense on corporate governance, the egregious neglect of shareholder interests and Pops destroying further shareholder value.

1 Estimated by subtracting the percentage change of Alkermes’ share price from the percentage change of IBB price from 12/30/16 to 12/30/21

Michael Hoak

ir@sarissacap.com

Source: Sarissa Capital Management LP

Alkermes Inc. plc

NASDAQ:ALKS

ALKS Rankings

ALKS Latest News

ALKS Stock Data

4.07B
158.79M
1.25%
108.01%
8.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
DUBLIN 4

About ALKS

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.